🇺🇸 FDA
Patent

US 8637026

Anti-C35 antibody combination therapies and methods

granted A61KA61K2039/507A61K2039/545

Quick answer

US patent 8637026 (Anti-C35 antibody combination therapies and methods) held by VACCINEX, INC. expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/507, A61K2039/545, A61P, A61P35/00